6-bromo-2-(dimethoxymethyl)quinoline | 439814-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-bromo-2-(dimethoxymethyl)quinoline
• CAS: 439814-98-9
• 化学式: C₁₂H₁₂BrNO₂
• 分子量: 282.137
• InChiKey: IONRUVOHCQCWJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-bromo-2-(dimethoxymethyl)quinoline 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 水 、 sodium carbonate 、 对甲苯磺酸 、 溶剂黄146 、 β-丙氨酸 作用下， 以 乙醇 、 丙酮 、 甲苯 为溶剂， 反应 20.0h， 生成 (E,Z)-5-((6-(1-oxo-1,3-dihydroisobenzofuran-5-yl)quinolin-2-yl)methylene)-2-thioxoimidazolidin-4-one
  参考文献：
  名称：

  Inhibition of the pore-forming protein perforin by a series of aryl-substituted isobenzofuran-1(3H)-ones

  摘要：

  An aryl-substituted isobenzofuran-1(3H)-one lead compound was identified from a high throughput screen designed to find inhibitors of the lymphocyte pore-forming protein perforin. A series of analogs were then designed and prepared, exploring structure-activity relationships through variation of 2-thioxoimidazolidin-4-one and furan subunits on an isobenzofuranone core. The ability of the resulting compounds to inhibit the lytic activity of both isolated perforin protein and perforin delivered in situ by intact KHYG-1 natural killer effector cells was determined. Several compounds showed excellent activity at concentrations that were non-toxic to the killer cells. This series represents a significant improvement on previous classes of compounds, being substantially more potent and largely retaining activity in the presence of serum. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.011
• 作为产物：
  描述：

  6-溴-2-甲基喹啉 在 sodium hydroxide 、 selenium(IV) oxide 、 对甲苯磺酸一水合物 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 以90%的产率得到6-bromo-2-(dimethoxymethyl)quinoline
  参考文献：
  名称：

  Telomerase inhibitors and methods of their use

  摘要：

  本文提供了噻唑烷二酮化合物、组合物和方法，用于体外抑制端粒酶活性以及体内和体外治疗由端粒酶介导的疾病或病症。本发明的方法、化合物和组合物可以单独使用，也可以与其他药理活性剂结合在一起，用于治疗由端粒酶活性介导的疾病或病症，例如癌症的治疗。还公开了用于检测或筛选端粒酶活性抑制剂的方法。

  公开号：

  US20020120144A1

文献信息

• US6452014B1
  申请人：——

  公开号：US6452014B1

  公开（公告）日：2002-09-17
• [EN] TELOMERASE INHIBITORS AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE LA TELOMERASE ET LEURS PROCEDES D'UTILISATION
  申请人：GERON CORP

  公开号：WO2002051409A1

  公开（公告）日：2002-07-04

  Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are methods for assaying or screening for inhibitors of telomerase activity.
• Inhibition of the pore-forming protein perforin by a series of aryl-substituted isobenzofuran-1(3H)-ones
  作者：Julie A. Spicer、Kristiina M. Huttunen、Christian K. Miller、William A. Denny、Annette Ciccone、Kylie A. Browne、Joseph A. Trapani

  DOI：10.1016/j.bmc.2011.12.011

  日期：2012.2

  An aryl-substituted isobenzofuran-1(3H)-one lead compound was identified from a high throughput screen designed to find inhibitors of the lymphocyte pore-forming protein perforin. A series of analogs were then designed and prepared, exploring structure-activity relationships through variation of 2-thioxoimidazolidin-4-one and furan subunits on an isobenzofuranone core. The ability of the resulting compounds to inhibit the lytic activity of both isolated perforin protein and perforin delivered in situ by intact KHYG-1 natural killer effector cells was determined. Several compounds showed excellent activity at concentrations that were non-toxic to the killer cells. This series represents a significant improvement on previous classes of compounds, being substantially more potent and largely retaining activity in the presence of serum. (C) 2011 Elsevier Ltd. All rights reserved.
• Telomerase inhibitors and methods of their use
  申请人：——

  公开号：US20020120144A1

  公开（公告）日：2002-08-29

  Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are methods for assaying or screening for inhibitors of telomerase activity.

  本文提供了噻唑烷二酮化合物、组合物和方法，用于体外抑制端粒酶活性以及体内和体外治疗由端粒酶介导的疾病或病症。本发明的方法、化合物和组合物可以单独使用，也可以与其他药理活性剂结合在一起，用于治疗由端粒酶活性介导的疾病或病症，例如癌症的治疗。还公开了用于检测或筛选端粒酶活性抑制剂的方法。